683 Capital Management’s Harmony Biosciences HRMY Stock Holding History

683 Capital Management’s Portfolio HRMY Stock Details HRMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$10.7M	Buy	+294,000	New	+$9.27M	0.53%	45
2026 Q1	–	Sell	-415,000	Closed	-$13.6M	–	250
2025 Q4	$15.5M	Buy	415,000 +133,000	+47%	+$4.37M	0.68%	33
2025 Q3	$7.77M	Sell	282,000 -20,000	-7%	-$689K	0.41%	54
2025 Q2	$9.54M	Buy	302,000 +2,000	+0.7%	+$64.3K	0.63%	47
2025 Q1	$9.96M	Hold	300,000	–	–	0.69%	42
2024 Q4	$10.3M	Hold	300,000	–	–	0.64%	41
2024 Q3	$12M	Buy	300,000 +5,000	+2%	+$176K	0.91%	33
2024 Q2	$8.9M	Hold	295,000	–	–	0.67%	43
2024 Q1	$9.91M	Sell	295,000 -30,000	-9%	-$963K	0.72%	42
2023 Q4	$10.5M	Sell	325,000 -25,000	-7%	-$698K	0.86%	45
2023 Q3	$11.5M	Buy	350,000 +50,000	+17%	+$1.74M	0.89%	36
2023 Q2	$10.6M	Buy	300,000 +150,000	+100%	+$5.18M	0.76%	37
2023 Q1	$4.9M	Buy	+150,000	New	+$6.83M	0.36%	72

Other funds holding HRMY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

683 Capital Management's HRMY Position: Q2 2026 in Review

683 Capital Management opened a new position in Harmony Biosciences (HRMY) in Q2 2026: 294,000 shares worth $10.7M. The stake represents 0.53% of the portfolio and ranks #45 among its holdings. This is a return to the name: 683 Capital Management previously reported a position in HRMY as recently as Q4 2025.

683 Capital Management first reported a position in HRMY in Q1 2023 and has held it in 13 quarters since. The position peaked at $15.5M in Q4 2025. 327 funds tracked by Wall St. Rank hold HRMY as of Q2 2026.

683 Capital Management held 294,000 shares of Harmony Biosciences worth $10.7M as of Q2 2026.
Harmony Biosciences was a new 683 Capital Management position in Q2 2026.
Harmony Biosciences made up 0.53% of 683 Capital Management's portfolio in Q2 2026, its #45 holding.
683 Capital Management first reported a position in Harmony Biosciences in Q1 2023 and has held it in 13 quarters since.
683 Capital Management's Harmony Biosciences position peaked at $15.5M in Q4 2025.
327 funds tracked by Wall St. Rank held Harmony Biosciences as of Q2 2026.

Based on 683 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.